Table 6.

Summary of treatment-related adverse events occurring in at least one subject

Adverse event, n (%)GTDS group 1 (N = 60)Intravenous granisetron group 2 (N = 60)Placebo group 3 (N = 60)Moxifloxacin group 4 (N = 60)
Subjects with at least one treatment-related adverse event29 (48)13 (22)21 (35)14 (23)
 Application site erythema13 (22)6 (10)7 (12)8 (13)
 Constipation10 (17)1 (2)1 (2)0 (0)
 Headache4 (7)6 (10)2 (3)2 (3)
 Dizziness2 (3)1 (2)2 (3)0 (0)
 Somnolence1 (2)3 (5)3 (5)1 (2)
 Application site pruritus1 (2)0 (0)3 (5)1 (2)
 Nausea1 (2)0 (0)2 (3)0 (0)
 Flushing1 (2)0 (0)1 (2)0 (0)
 Abdominal pain1 (2)0 (0)0 (0)0 (0)
 Cardiac palpitations1 (2)0 (0)0 (0)0 (0)
 Dry mouth1 (2)0 (0)0 (0)0 (0)
 Irregular menstruation1 (2)0 (0)0 (0)0 (0)
 Pain in extremity1 (2)0 (0)0 (0)0 (0)
 Tremor1 (2)0 (0)0 (0)0 (0)